LCAR-AIO for relapsed or hard-to-treat lupus
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study tests a new treatment called LCAR-AIO for people with systemic lupus erythematosus (SLE) that has come back or not responded well to standard therapies. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with lupus for at least 6 months.
- Your lupus has come back or did not get better with other treatments.
- You have certain lupus-related antibodies in your blood, like ANA, anti-dsDNA, or anti-Sm.
- You are not pregnant, breastfeeding, or planning pregnancy for at least a year after treatment.
- You do not have active infections like hepatitis or tuberculosis, or other serious health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
This trial tests a new treatment using your own immune cells (CAR T-cells) targeted at a marker called CD19. It is for people whose lupus or myositis has not been controlled by other treatments.
This trial tests a new type of cell treatment (BCMA-CD19 cCAR T cells) for people with lupus that has not responded well to standard therapies. It may help reduce lupus disease activity.
This trial tests a new CAR T-cell therapy (C-CAR168) for people with lupus nephritis that has not responded to standard treatments. It aims to see if this therapy can help control the disease.
This trial tests a new CAR-T cell treatment for adults with systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. It aims to see if targeting CD19 cells can calm the disease.
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.